Enliven Therapeutics extends cash runway into 2030
The biotechnology company ended the second quarter with $895.2 million in cash and marketable securities
Enliven Therapeutics (ELVN) reported a widened net loss for the second quarter of 2026, though the company significantly bolstered its liquidity position. The biotechnology developer used the period to secure funding that extends its operational horizon by several years.
Net loss for the second quarter rose to $32.5 million, compared to a net loss of $25.3 million in the second quarter of 2025. The increase in losses followed a rise in operating costs as the company advanced its clinical programs.
Research and development expenses climbed to $29.0 million from $21.5 million in the prior-year quarter. General and administrative expenses also increased, rising to $8.2 million from $7.1 million during the same period last year.
Despite the higher spending, Enliven strengthened its balance sheet through a public offering in June 2026. The offering expected gross proceeds of approximately $400 million, which contributed to a cash, cash equivalents, and marketable securities balance of $895.2 million as of June 30, 2026. This represents a substantial increase from the $462.6 million held as of December 31, 2025.
The reinforced capital position is now expected to extend its cash runway into 2030.
On the regulatory front, Enliven's lead candidate, ELVN-001, received Fast Track Designation from the FDA.